SCHEMBL9979920

SCHEMBL9979920

Cn1c2ccc(-n3c4ccccc4c4ccccc43)cc2c2cc3c(cc21)c1cc(-n2c4ccccc4c4ccccc42)ccc1n3C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.57
KDM4E B2RXH2 6/20 0.53
MAPT P10636 4/20 0.53
HPGD P15428 4/20 0.53
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
HSD17B10 Q99714 2/20 0.53
MEN1 O00255 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
ATM Q13315 2/20 0.48
PABPC1 P11940 1/20 0.47
KIF11 P52732 1/20 0.47
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NPY5R Q15761 1/20 0.42
ALKBH5 Q6P6C2 1/20 0.41
FTO Q9C0B1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10450123 0.96 GPR3 (0.61) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL11940264 0.96 GPR3 (0.61) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL16791290 0.96 GPR3 (0.61) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL17676358 0.95 GPR3 (0.55) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL17676398 0.95 GPR3 (0.55) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL17904086 0.95 GPR3 (0.55) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL18415783 0.94 KDM4E (0.56) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL17676377 0.93 GPR3 (0.53) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL17676359 0.93 GPR3 (0.53) GPR3KDM4EMAPTHPGDALDH1A1
SCHEMBL23373437 0.92 KDM4E (0.58) GPR3KDM4EMAPTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2012-06-21 US disclosed
US-8110690-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2012-02-07 US disclosed
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2009-02-05 US disclosed
US-7456424-B2 Thin film transistors including indolocarbozoles XEROX CORPORATION (US) 2008-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT GPR3 1112/4885KDM4E 2878/4885MAPT 196/4885
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT GPR3 1112/4885KDM4E 2878/4885MAPT 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.